The survival difference between the two groups was statistically significant (P = 0.0063), suggesting that the PLK1 expression level might be a potential predictor of survival prognosis in EGFR-mutant NSCLC patients (Fig. 1J). This evidence concerns the gene PLK1 and non-small cell lung carcinoma.